Mitochondria News
-
CD Genomics Unveils Advanced Mitochondrial Diseases Panel Sequencing Service
CD Genomics, a leading biotechnology company specializing in genomics and sequencing, has announced the launch of its advanced Mitochondrial Diseases Panel Sequencing services. This new panel enables rapid and accurate detection of mutations in mitochondrial DNA (mtDNA) that are associated with a wide range of mitochondrial disorders. Mitochondrial diseases are a complex and heterogeneous group ...
By CD Genomics
-
CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials ?
Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases CY6463 favorable tolerability and safety profile was confirmed Ariana Pharma, a leading Artificial Intelligence (AI) drug development company, in collaboration with Cyclerion Therapeutics, presented today safety and pharmacodynamic results ...
-
NeuroPointDX to Present Precision Medicine Approaches to Diagnosing and Treating Autism at National TACA Autism Conference
NeuroPointDX, a business unit of Stemina Biomarker Discovery, today announced the company will present recent data from the Children’s Autism Metabolome Project (CAMP), its large, comprehensive clinical study, supporting its precision medicine approach to the diagnosis and treatment of autism spectrum disorder (ASD) at the National TACA Autism Conference. CAMP is the largest clinical study ...
By NeuroPointDX
-
Cell Apoptosis Kits at Creative Biogene: Efficient and Convenient
Creative Biogene unveiled a rich portfolio of efficient cell apoptosis assay kits targeted to detect mitochondrial permeability transition pore (MPTP) as well as mitochondrial membrane potential (MMP) to assist researchers in mitochondrial studies. Mitochondrial dysfunction has been linked to a variety of market therapeutics and pathological diseases. Therefore, studying or maintaining ...
-
Creative Biogene Releases Comprehensive Mitochondrial Gene Expression Services
Creative Biogene today released comprehensive mitochondrial gene expression services with streamlined project procedures and high-standard mtDNA expression results. "For years, we have been engaged in the mitochondrial study. Our scientists explore mitochondrial gene expression via mtDNA microarray expression profiling, gene chip data mining, key gene & protein verification, and functional ...
-
New scientific paper published on the mechanism of action of Polyphenon E, a defined extract from green tea leaves, in preliminary stages of skin cancer
DERMAGO GmbH today announced the publication of an article by the research group of PD Dr. J. Eberle from Charité-Universitätsmedizin Berlin, Germany. The article entitled “Inhibition of Cell Proliferation and Cell Viability by Sinecatechins in Cutaneous SCC Cells Is Related to an Imbalance of ROS and Loss of Mitochondrial Membrane Potential” was released in the ...
-
One-stop Mitochondria-focused Testing Services Targeting to Preclinical Studies of Cardiac Diseases
New York, United States—June 28, 2022—Creative Biogene offers one-stop mitochondria-focused testing services for the evaluation of a variety of cardiac diseases associated with mitochondrial dysfunction, which can provide insights and potential treatments for mitochondrial disorders in the preclinical stages. With its ready-to-use models and assays for cardiac diseases, customers can accurately ...
-
Full-Scale Mitochondrial Bioenergetics Services at Creative Biogene
New York, United States—May 18, 2022—As one of leading bio-companies engaged in mitochondrial research, Creative Biogene, together with its large team of experts, create a powerful mitochondrial research service platform. To satisfy the research needs of global customers on mitochondrial bioenergies, Creative Biogene provides partners with comprehensive range of mitochondrial bioenergetics ...
-
CD Genomics Releases Human Mitochondrial DNA Sequencing for Disease Research and Biodiversity Assessment
CD Genomics is a world-leading genomics services company, innovating in sequencing services for the genomics industry as well as genotyping, library construction, bioinformatics, aptamers, microarrays, health diagnostics, mutagenesis analysis, and more. CD Genomics launches fully-developed human mitochondrial DNA (mtDNA) sequencing for the study of mitochondrial genome-related diseases, such as ...
By CD Genomics
-
In-depth Mitochondrial Function Testing Services at Creative Biogene
New York, United States—April 21, 2022—Defects in mitochondrial function have long been suspected of contributing to the development of cancer. In this regard, Creative Biogene strives to explore mitochondrial functions that are yet to be discovered as well as the pathogenesis of mitochondria-associated cancers and possible interventions through in-depth mitochondrial function testing ...
-
Neuropathix, Inc. Receives Patent Grant from India for its Novel Anti-Inflammatory Compounds
DOYLESTOWN, PA / ACCESSWIRE / January 18, 2022 / Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces that the Company has been issued Indian Patent IN201617027528 specific to its global patent known as WO2015/106108A2 titled, “Novel Functionalized 1,3-Benzene Diols and their ...
-
CELLVIE featured in Biocentury`s Emerging Company Profile
Harvard spinout cellvie is pioneering therapeutic mitochondria transplantation as a way to rescue cell energy metabolism and save cells that would otherwise die. James McCully, a cellvie AG co-founder, developed the approach at Harvard Medical School to ameliorate ischemia-reperfusion injury, which is the tissue damage caused when the blood supply returns after a period of ischemia. "What Jim ...
By cellvie Inc.
-
TIKOMED’S ILB® attenuates clinical symptoms and serum biomarkers of oxidative/nitrosative stress and mitochondrial dysfunction in patients with ALS in data published by the Journal of Personalized Medicine
New study results for Tikomed’s platform lead drug candidate ILB® in the treatment of patients with amyotrophic lateral sclerosis (ALS), have now been published in the Journal of Personalized Medicine. The data revealed a significant normalization of the serum levels of several key metabolites in addition to a significant improvement of patients’ clinical conditions for the ...
By TIKOMED AB
-
Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN
Kannalife, Inc. (OTCQB: KLFE) (“Kannalife” or the “Company”), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today that it has completed its phase 1 study funded by a grant (1R41DA044898-01) from the National Institutes of Health’s (NIH) National Institute on Drug Abuse (NIDA). The study was performed ...
-
New Metabolic Biomarkers Open Door to Earlier Diagnosis, More Precise and Individualized Treatment of Children at Risk for Autism
Continued analysis of samples from the Children’s Autism Metabolome Project (CAMP), the most comprehensive clinical study of metabolism in children who have autism spectrum disorder (ASD) conducted to date, has identified three new areas of metabolism that affect the biology of children with ASD. These include biomarkers indicating that altered neurotransmission, energy metabolism, and ...
By NeuroPointDX
-
Seahorse Executive Jay Teich Receives SFRBM CEO Innovator Award
Jay Teich, former Seahorse Bioscience CEO, received the first-ever CEO Innovator Award from the Society for Redox Biology and Medicine (SFRBM). This international award recognizes industry leaders who have transformed the face of scientific research in the areas of redox biology and medicine. Teich received the award in Boston on Nov. 20 during SFRBM 2015, the premier event for cutting-edge ...
-
Agilent Technologies Completes Acquisition of Seahorse Bioscience, Industry Leader in Tools for Measuring Cell Metabolism
Agilent Technologies Inc. today announced it has completed the acquisition of Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics. Agilent announced its intent to acquire Seahorse on Sept. 9. Seahorse's leading technology enables researchers to better understand cell health, function and signaling, and how the cell may be impacted ...
-
Agilent Technologies to Acquire Seahorse Bioscience, Industry Leader in Tools for Measuring Cell Metabolism
Agilent Technologies Inc. (NYSE: A) and Seahorse Bioscience today announced they have signed a definitive agreement under which Agilent will acquire Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics. Exploration into cell metabolism is rapidly accelerating as the links between mitochondrial function and disease are increasingly ...
-
Berkeley lab awarded $12.8 million in stimulus funds for health research
Lawrence Berkeley National Laboratory has been awarded $12.8 million in American Recovery and Reinvestment Act funding by the National Institutes of Health (NIH) for research into cancer, neurodegenerative diseases, radioactive decontamination and a variety of other health conditions. The grants bring Berkeley Lab’s total Recovery Act funding to more than $240 million in areas covering energy, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you